Abstract
The aromatase inhibitor CGS-16949A was used to determine whether CGS-16949A altered secretion of progesterone, estradiol-17β, PGE (PGE 1 + PGE 2), PGF 2α and PSPB. Ninety day pregnant ewes were ovariectomized and received vehicle, PGF 2α, CGS-16949A or PGF 2α+CGS-16949A. None of the ewes treated with PGF 2α, CGS-16949A or PGF 2α+CGS-16949A aborted ( P ≥ 0.05) during the 108-h experimental period. Treatment with CGS-16949A lowered ( P ≤ 0.05) progesterone in jugular venous plasma but concentrations of progesterone were not affected ( P ≥ 0.05) by treatment with PGF 2α. Concentrations of estradiol-17β and PSPB in jugular venous plasma and PGE in inferior vena cava plasma were decreased ( P ≤ 0.05) by treatment with CGS-16949A. Concentrations of PGF 2α in inferior vena cava plasma were not affected ( P ≥ 0.05) by treatment with CGS-16949A. Decreases in estradiol-17β occurred before decreases in PSPB, which was then followed by decreases in PGE ( P ≤ 0.05). It is concluded that these data support the hypothesis that estradiol-17β regulates placental secretion of PSPB; PSPB regulates placental secretion of PGE; and PGE regulates placental secretion of progesterone during mid-pregnancy in ewes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
